New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 16, 2014
05:46 EDTACT, CELGCelgene presented strong case against Actavis, says Piper Jaffray
Piper Jaffray believes Celgene's (CELG) council presented a strong case against Actavis (ACT) at yesterday's Markman Hearing for disputed claims regarding isomer/mixture adpolymorph "form A" and "form B." Piper thinks Celgene's case may help in settlement negotiations and it keeps an Overweight rating on the stock with a $170 price target.
News For CELG;ACT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
April 30, 2015
07:32 EDTCELGCelgene reports Q1 adjusted EPS $1.07, consensus $1.06
Subscribe for More Information
April 29, 2015
15:00 EDTCELGNotable companies reporting before tomorrow's open
Subscribe for More Information
07:16 EDTCELGAgios Pharmaceuticals plans to advance AG-881 to clinical development
Subscribe for More Information
April 28, 2015
17:00 EDTACTActavis, Medicines360 announce publication of ACCESS IUS study of LILETTA
Actavis and Medicines360, a nonprofit women's health pharmaceutical company, announced that the initial results of ACCESS IUS, or A Comprehensive Contraceptive Efficacy and Safety Study of an IUS, were published online today in the medical journal Contraception. The study found that LILETTA, or levonorgestrel-releasing intrauterine system, 52 mg, is 99.45% effective for the prevention of pregnancy for up to three years of use in women aged 16-35 regardless of race, parity, or body mass index. The ACCESS IUS trial is still ongoing and will evaluate the efficacy and safety of LILETTA for up to seven years of use.
10:19 EDTACTPershing Square lists Herbalife, Actavis as top Q1 losers
Subscribe for More Information
05:53 EDTCELGStocks with implied volatility movement; AMGN CELG
Subscribe for More Information
April 27, 2015
07:31 EDTCELGCelgene to acquire Quanticel Pharmaceuticals for $100M in cash
Subscribe for More Information
April 26, 2015
12:50 EDTCELGApple, Celgene, others are 'top picks' for spring, Barron's says
In a survey of U.S. money managers, shares of Apple (AAPL), Dow Chemical (DOW), American Airlines (AAL), Celgene (CELG), General Motors (GM), and McDermott (MDR) were identified as top picks for this spring, Barron's contends in its cover story. Reference Link
April 24, 2015
10:59 EDTCELGCelgene call activity attributed to vague takeover speculation
Subscribe for More Information
10:22 EDTCELGRumor: Celgene active on vague takeover speculation
Celgene (CELG) shares are active on speculation Bristol-Myers (BMY) may be interested in acquiring the company.
09:27 EDTACTActavis' Dalvance shows positive Phase 3 results for skin infections
Actavis announced positive top-line results for study DUR001-303, a phase 3 study comparing a single 1500 mg dose of Dalvance with the same total dose given as two-doses one week apart, for the treatment of acute bacterial skin and skin structure infections caused by susceptible Gram-positive bacteria, including methicillin resistant Staphylococcus aureus. Preliminary top-line data demonstrated the 1500 mg single-dose of Dalvance achieved its primary endpoint of non-inferiority to the two-dose regimen at 48-72 hours after initiation of therapy. Actavis plans to file a supplemental New Drug Application with these data in Q3.
07:09 EDTACTCipher Pharmaceuticals announces Markman hearing in Absorica patent suit
Subscribe for More Information
05:39 EDTCELGCelgene announces strategic collaboration with AstraZeneca
Subscribe for More Information
April 23, 2015
17:45 EDTCELGCelgene announces fulfillment of approval requirements for POMALYST
Subscribe for More Information
09:20 EDTCELGCelgene patent latest to be challenged by Hayman Capital's Bass
The Coalition For Affordable Drugs, a group linked to Hayman Capital's Kyle Bass, has requested an Inter Partes Review of Claims 110 of U.S. Patent No. 6,045,501 held by Celgene (CELG), according to a USPTO filing. The 501 patent claims methods for delivering a drug, including a teratogenic drug, to a patient while preventing the exposure of a fetus or other contraindicated individuals to the drug. The patent is related to the company's Revlimid drug. BACKGROUND: Previously, the same coalition requested an Inter Partes Review of patents held by Pharmacyclics (PCYC), Acorda Therapeutics (ACOR), Shire (SHPG) and Jazz Pharmaceuticals (JAZZ). On January 7, Reuters reported that Bass planned to take "around 15 pharmaceutical companies with a combined market capitalization of $450B" into an Inter Partes Review for extending patents in questionable ways, citing a presentation made by Bass in Oslo. PRICE ACTION: Shares of Celgene are down 0.5% to $114.92 in pre-market trading.
08:16 EDTACTActavis launches Avycaz anti-infective in U.S.
Subscribe for More Information
April 22, 2015
07:37 EDTACTOrexigen and Takeda receive Paragraph IV certification notice
Subscribe for More Information
April 20, 2015
16:22 EDTACTActavis reports CCO Charles Mayr to retire for health reasons
Subscribe for More Information
08:12 EDTACTActavis's BOTOX label approved by FDA for spasticity treatment
Subscribe for More Information
07:18 EDTACTAmerican Academy of Neurology to hold annual meeting
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use